Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H15FO3 |
| Molecular Weight | 286.2976 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@H](CC(=O)C1=CC=C(F)C=C1)CC2=CC=CC=C2
InChI
InChIKey=DZRBTTWGDHUKDS-AWEZNQCLSA-N
InChI=1S/C17H15FO3/c18-15-8-6-13(7-9-15)16(19)11-14(17(20)21)10-12-4-2-1-3-5-12/h1-9,14H,10-11H2,(H,20,21)/t14-/m0/s1
| Molecular Formula | C17H15FO3 |
| Molecular Weight | 286.2976 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:56:55 GMT 2023
by
admin
on
Fri Dec 15 15:56:55 GMT 2023
|
| Record UNII |
XBQ44I1GX2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
XBQ44I1GX2
Created by
admin on Fri Dec 15 15:56:55 GMT 2023 , Edited by admin on Fri Dec 15 15:56:55 GMT 2023
|
PRIMARY | |||
|
203855-57-6
Created by
admin on Fri Dec 15 15:56:55 GMT 2023 , Edited by admin on Fri Dec 15 15:56:55 GMT 2023
|
PRIMARY | |||
|
133082904
Created by
admin on Fri Dec 15 15:56:55 GMT 2023 , Edited by admin on Fri Dec 15 15:56:55 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Mechanism of Action: B cell stimulant; Highest Development Phase: Discontinued for Insulin resistance, Type 2 diabetes mellitus; Most Recent Events: 15 May 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (PO), 15 May 2003 Discontinued - Phase-II for Insulin resistance in Europe (unspecified route)
|
